Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 A, 2009, Pages 2899-2910

  Dong, Yunzhou ^a   Wu, Yong ^a   Wu, Mingyuan ^a   Wang, Shuangxi ^a   Zhang, Junhua ^a   Xie, Zhonglin ^a   Xu, Jian ^a   Song, Ping ^a   Wilson, Kenneth ^a   Zhao, Zhengxing ^a   Lyons, Timothy ^a   Zou, Ming Hui ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium homeostasis; Calpain activation; Endothelium dysfunction; ENOS, heavily oxidized and glycated LDL (HOG LDL); Nitric oxide

Indexed keywords

CALCIUM; CALPAIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOSYLATED LIPOPROTEINS, LDL; LOW DENSITY LIPOPROTEIN; NEUTROPHIL CYTOSOLIC FACTOR 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEASOME; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL; ARTICLE; C57BL MOUSE; CATTLE; CYTOPLASM; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOUSE; PROTEIN PROCESSING; PROTEIN TRANSPORT; TIME;

ANIMALS; CALCIUM; CALPAIN; CATTLE; CYTOPLASM; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SPACE; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES; TIME FACTORS; TRANSCRIPTION, GENETIC;

BOVINAE; SUIDAE;

EID: 72849111282     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00416.x     Document Type: Article

References (45)

1. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res. 2007 4 : 5 8.
2. Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a "carbonyl stress" hypothesis. Diabetes Rev. 1997 5 : 365 391.
3. Tsimikas S, Glass C, Steinberg D. Lipoproteins, lipoprotein oxidation and atherogenesis. In : Chien KR, editor. Molecular basis of cardiovascular disease: a companion to Braunwald's heart disease. Philadelphia : W.B. Saunders Company 2004. pp. 385 413.
4. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995 46 : 223 234.
5. Kennedy AL, Lyons TJ. Glycation, oxidation, and lipoxidation in the development of diabetic complications. Metabolism. 1997 46 : 14 21.
6. Gugliucci Creriche A, Dumont S, Siffert JC, et al. In vitro glycated low-density lipoprotein interaction with human monocyte-derived macrophages. Res Immunol. 1992 143 : 17 23.
7. Kobayashi K, Watanabe J, Umeda F, et al. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J. 1995 42 : 461 465.
8. Millican SA, Schultz D, Bagga M, et al. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Radic Res. 1998 28 : 533 542.
9. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006 113 : 1708 1714.
10. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994 23 : 1121 1131.
11. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 24 : 998 1005.
12. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004 11 : 89 97.
13. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat. 2007 82 : 119 127.
14. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004 45 : 993 1007.
15. Matsumoto T, Takashima H, Ohira N, et al. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol. 2004 44 : 451 457.
16. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol. 2006 17 : 502 509.
17. Jenkins AJ, Velarde V, Klein RL, et al. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes 2000 49 : 2160 2169.
18. Xu J, Xie Z, Reece R, et al. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006 26 : 2688 2695.
19. Xie Z, Dong Y, Scholz R, et al. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008 117 : 952 962.
20. Zhang M, Dong Y, Xu J, et al. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res. 2008 102 : 328 337.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001 29 : e45.
22. Dong Y, Tan J, Cui MZ, et al. Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation. FASEB J. 2006 20 : 331 333.
23. Xu J, Wu Y, Song P, et al. Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation. 2007 116 : 944 953.
24. Xie Z, Dong Y, Zhang M, et al. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem. 2006 281 : 6366 6375.
25. Klein RL, Semler AJ, Baynes JW, et al. Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann N Y Acad Sci. 2005 1043 : 379 389.
26. Stalker TJ, Gong Y, Scalia R. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes. 2005 54 : 1132 1140.
27. Jiang J, Cyr D, Babbitt RW, et al. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP. J Biol Chem. 2003 278 : 49332 49341.
28. Johnson GV, Guttmann RP. Calpains: intact and active Bioessays. 1997 19 : 1011 1018.
29. Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med. 2001 7 : 355 362.
30. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol. 2000 150 : 887 894.
31. Minshall RD, Sessa WC, Stan RV, et al. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol. 2003 285 : 1179 1183.
32. Chen K, Thomas SR, Keaney JF Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic Biol Med. 2003 35 : 117 132.
33. Li JM, Mullen AM, Yun S, et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res. 2002 90 : 143 150.
34. O'Donnell RW, Johnson DK, Ziegler LM, et al. Endothelial NADPH oxidase: mechanism of activation by low-density lipoprotein. Endothelium. 2003 10 : 291 297.
35. Stangl V, Lorenz M, Meiners S, et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J. 2004 18 : 272 279.
36. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999 43 : 562 571.
37. Oemar BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998 97 : 2494 2498.
38. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999 399 : 601 605.
39. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000 477 : 258 262.
40. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci. 2002 962 : 122 130.
41. Goll DE, Thompson VF, Li H, et al. The calpain system. Physiol Rev. 2003 83 : 731 801.
42. Stalker TJ, Skvarka CB, Scalia R. A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J. 2003 17 : 1511 1513.
43. Su Y, Block ER. Role of calpain in hypoxic inhibition of nitric oxide synthase activity in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2000 278 : 1204 1212.
44. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000 26 : 163 175.
45. 2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation. 2008 117 : 52 60.